scholarly journals Adiponectin, total anti-oxidant status, and high sensitivity C-reactive protein in Indonesian men with metabolic syndrome

2009 ◽  
pp. 262 ◽  
Author(s):  
Cynthia R. Sartika ◽  
Widjaja Lukito ◽  
Andi Wijaya
Keyword(s):  
Metabolic Syndrome ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Anti Oxidant ◽  
Oxidant Status

scholarly journals Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Mónica Acevedo ◽  
Paola Varleta ◽  
Verónica Kramer ◽  
Giovanna Valentino ◽  
Teresa Quiroga ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Phospholipase A2 ◽  
High Sensitivity ◽  
Roc Curves ◽  
Activity Levels ◽  
Pla2 Activity ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Cv Disease

High sensitivity C-reactive protein (hsCRP) is a marker of metabolic syndrome (MS) and cardiovascular (CV) disease. Lipoprotein-associated phospholipase A2 (Lp-PLA2) also predicts CV disease. There are no reports comparing these markers as predictors of MS.Methods. Cross-sectional study comparing Lp-PLA2 and hsCRP as predictors of MS in asymptomatic subjects was carried out; 152 subjects without known atherosclerosis participated. Data were collected on demographics, cardiovascular risk factors, anthropometric and biochemical measurements, and hsCRP and Lp-PLA2 activity levels. A logistic regression analysis was performed with each biomarker and receiver operating characteristic (ROC) curves were constructed for MS.Results. Mean age was 46 ± 11 years, and 38% of the subjects had MS. Mean Lp-PLA2 activity was 185 ± 48 nmol/mL/min, and mean hsCRP was 2.1 ± 2.2 mg/L. Subjects with MS had significantly higher levels of Lp-PLA2 (P=0.03) and hsCRP (P<0.0001) than those without MS. ROC curves showed that both markers predicted MS.Conclusion. Lp-PLA2 and hsCRP are elevated in subjects with MS. Both biomarkers were independent and significant predictors for MS, emphasizing the role of inflammation in MS. Further research is necessary to determine if inflammation predicts a higher risk for CV events in MS subjects.

scholarly journals The Effect of Tempe Gembus on High-Sensitivity C-Reactive Protein and Adiponectine Levels in Rats with Metabolic Syndrome

2020 ◽  
Vol 66 (Supplement) ◽  
pp. S51-S55
Author(s):  
Ikawati SULISTYANINGSIH ◽  
Diana Nur AFIFAH ◽  
Achmad Zulfa JUNIARTO ◽  
Gemala ANJANI ◽  
Ninik RUSTANTI
Keyword(s):  
Metabolic Syndrome ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Correlation of Ferritin and Transferrin Serum with hsCRP and F2-Isoprostane in Metabolic Syndrome

2010 ◽  
Vol 2 (3) ◽  
pp. 131
Author(s):  
Waode Nurfina ◽  
Irawan Yusuf ◽  
Mansyur Arif
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Iron Status ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
The Metabolic Syndrome ◽  
Metabolic Conditions ◽  
Inflammatory State ◽  
And Oxidative Stress

BACKGROUND: The low inflammatory state that accompanies the Metabolic Syndrome (MetS) associates with the overexpression of oxidative stress. Ferritin and Transferrin serum are often used to measure iron status and their concentrations are altered in several metabolic conditions. We hypothesized that concentration of Ferritin and Transferrin serum increase in Metabolic Syndrome (MetS) and correlate with the inflammation and oxidative stress.METHODS: We studied 65 male MetS patients, aged 43.26±7.16 years. Iron metabolism was measured by concentration of Ferritin and Transferrin serums, while inflammatory and oxidative stress by high sensitivity C-reactive Protein (hsCRP) and F2-Isoprostane.RESULTS: Concentration of Ferritin 315.70±188.63 ng/L and Transferrin 2.36±0.31 g/L increased along with increasing components of MetS. Concentration of Ferritin serum had a positive correlation with hsCRP (r=0.220) and F2-Isoprostane (r=0.023).CONCLUSION: Serum concentration of Ferritin increased in the MetS and correlates with hsCRP and F2-Isoprostane.KEYWORDS: metabolic syndrome, ferritin, transferrin, hsCRP, F2-isoprostane

Metabolic syndrome in human immunodeficiency virus-infected patients

2018 ◽  
Vol 29 (11) ◽  
pp. 1089-1097 ◽  
Author(s):  
M Duro ◽  
MC Manso ◽  
S Barreira ◽  
I Rebelo ◽  
R Medeiros ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Acute Infection ◽  
Density Lipoprotein ◽  
Total Antioxidant Status ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Infection Treatment ◽  
Immunodeficiency Virus ◽  
Total Antioxidant

The objective of this study was to investigate the factors underlying the development of metabolic syndrome (MetS) in HIV-infected patients. Two hundred and sixty-six clinical cases were selected for a retrospective study. The sample was classified using the Adult Treatment Panel III guidelines and the identification of risk or protective factors associated with MetS evaluated via multivariate logistic or multinomial regressions. HIV-infected individuals diagnosed with MetS tend to be older, overweight, or obese (85% have a BMI ≥ 25), with a waist circumference > 90 cm (96.5 [88.8–105.5] cm, median [interquartile range]). Blood testing these individuals revealed high fasting levels of insulin (8.1 [5.8–21.6] pg/ml), glucose (98.0 [84.0–116.0] mg/dl), triglycerides (201.0 [142.0–267.3] mg/dl), and high-density lipoprotein cholesterol (36.5 [29.8–43.3] mg/dl) in addition with higher levels of inflammatory mediators such as high-sensitivity C-reactive protein (2.5 [1.0–4.9] mg/dl) and interleukin-6 (3.4 [2.8–3.8] pg/ml). The likelihood of HIV-infected individuals who are virally suppressed developing MetS is about 60% higher than those with acute infection. Treatment with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) increases the chance of developing MetS by around 2.4 times. Individuals with a lower antioxidant capacity (total antioxidant status [TAS] <1.33) have a 2.6 times higher risk of developing MetS. HIV-related chronic inflammation, a low TAS, and treatment with NRTIs in association with PIs are additional MetS risk factors.

Sign in / Sign up

Export Citation Format

Share Document